Consequently, in our opinion, an enhancement of mitochondrial function could be a promising strategy for tumor immunotherapy that could be used in combination with the current checkpoint blockade therapies available, such as anti-PD-L1, PD-1, and CTLA-4. Here, CTLA4 is linked to neoplasm.